Kymera Therapeutics, Inc.

KYMR · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$224-$147-$155-$100
Dep. & Amort.$7$4$3$2
Deferred Tax$0$0$0$0
Stock-Based Comp.$55$43$35$25
Change in WC-$24$9-$38-$62
Other Non-Cash-$9-$12$1$6
Operating Cash Flow-$195-$103-$153-$129
Investing Activities
PP&E Inv.-$13-$34-$3-$2
Net Acquisitions$0$0-$21$6
Inv. Purchases-$901$0-$446-$456
Inv. Sales/Matur.$496$0$469$358
Other Inv. Act.$14$174$21-$6
Investing Cash Flow-$404$140$21-$100
Financing Activities
Debt Repay.-$2-$0-$1-$1
Stock Issued$597$0$150$243
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$14$4$4$8
Financing Cash Flow$609$4$153$250
Forex Effect$0$0$0$0
Net Chg. in Cash$10$41$20$21
Supplemental Information
Beg. Cash$116$75$54$33
End Cash$126$116$75$54
Free Cash Flow-$207-$137-$156-$131